Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

BACKGROUND: Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer. MATERIALS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Nicolas, Isambert, Nicolas, Gomez-Roca, Carlos, Goeldner, Rainer-Georg, Zanetta, Sylvie, Sadrolhefazi, Behbood, de Mont-Serrat, Hélène, Campone, Mario, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664/
https://www.ncbi.nlm.nih.gov/pubmed/30350178
http://dx.doi.org/10.1007/s00280-018-3689-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664/
https://www.ncbi.nlm.nih.gov/pubmed/30350178
http://dx.doi.org/10.1007/s00280-018-3689-2

Ejemplares similares